Wakita A - Search Results

1

Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation.

Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H, Iida H, Shimokawa T, Kohno A, Mizuta S, Maruyama F, Wakita A, Kitaori K, Yano K, Hamaguchi M, Hamajima N, Morishima Y, Kodera Y, Sao H, Morishita Y. Yanada M, et al. Among authors: wakita a. Bone Marrow Transplant. 2003 Oct;32(8):801-7. doi: 10.1038/sj.bmt.1704232. Bone Marrow Transplant. 2003. PMID: 14520425

2

Twenty years' experience in allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in the Nagoya Blood and Marrow Transplantation Group.

Iida H, Sao H, Kitaori K, Gotoh S, Yazaki M, Kojima S, Wakita A, Morishima Y, Kodera Y, Morishita Y. Iida H, et al. Among authors: wakita a. Int J Hematol. 2004 Jan;79(1):79-84. doi: 10.1007/BF02983538. Int J Hematol. 2004. PMID: 14979483 Review.

3

Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation.

Atsuta Y, Suzuki R, Yamamoto K, Terakura S, Iida H, Kohno A, Naoe T, Yano K, Wakita A, Taji H, Hamaguchi M, Kodera Y, Sao H, Morishima Y, Hamajima N, Morishita Y. Atsuta Y, et al. Among authors: wakita a. Bone Marrow Transplant. 2006 Feb;37(3):289-96. doi: 10.1038/sj.bmt.1705247. Bone Marrow Transplant. 2006. PMID: 16400341

4

No significant association between HA-1 incompatibility and incidence of acute graft-versus-host disease after HLA-identical sibling bone marrow transplantation in Japanese patients.

Murata M, Emi N, Hirabayashi N, Hamaguchi M, Goto S, Wakita A, Tanimoto M, Saito H, Kodera Y, Morishita Y; Nagoya Blood and Marrow Transplantation Group. Murata M, et al. Among authors: wakita a. Int J Hematol. 2000 Oct;72(3):371-5. Int J Hematol. 2000. PMID: 11185997

5

Posttreatment nadir M-protein level is a stronger discriminator of survival following plateau attainment than is percent reduction in M-protein in patients with IgG myeloma.

Shimizu K, Nagura E, Hirabayashi N, Wakita A, Takeyama H, Sao H, Nitta M, Kawashima K, Saito H. Shimizu K, et al. Among authors: wakita a. Int J Hematol. 2001 Aug;74(2):205-8. doi: 10.1007/BF02982006. Int J Hematol. 2001. PMID: 11594523

6

[DAD, new intensive chemotherapy for patients with myeloma: a preliminary report].

Miwa H, Nagura E, Shimizu K, Nitta M, Ichikawa A, Ohno T, Kinoshita T, Shibata T, Sao H, Murase T, Takeyama H, Wakita A, Saito H; Nagoya Myeloma Study Group. Miwa H, et al. Among authors: wakita a. Rinsho Ketsueki. 2002 Nov;43(11):982-7. Rinsho Ketsueki. 2002. PMID: 12508483 Japanese.

7

Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.

Ito Y, Wakita A, Takada S, Mihara M, Gotoh M, Ohyashiki K, Ohtake S, Miyawaki S, Ohnishi K, Naoe T. Ito Y, et al. Among authors: wakita a. Int J Hematol. 2012 Oct;96(4):485-91. doi: 10.1007/s12185-012-1165-z. Epub 2012 Sep 6. Int J Hematol. 2012. PMID: 22956429 Clinical Trial.

8

Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200.

Harada K, Doki N, Miyazaki Y, Wakita A, Ohtake S, Takada S, Komatsu H, Kubo K, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Naoe T, Ohashi K. Harada K, et al. Among authors: wakita a. Ann Hematol. 2018 Aug;97(8):1481-1483. doi: 10.1007/s00277-018-3281-1. Epub 2018 Mar 1. Ann Hematol. 2018. PMID: 29497807 Clinical Trial. No abstract available.

9

Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study.

Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H, Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Ohnishi K, Miyawaki S, Naoe T, Ueda R, Ohno R. Wakita A, et al. Int J Hematol. 2012 Jul;96(1):84-93. doi: 10.1007/s12185-012-1105-y. Epub 2012 May 26. Int J Hematol. 2012. PMID: 22639053 Clinical Trial.

10

Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations.

Hanamura I, Iida S, Akano Y, Hayami Y, Kato M, Miura K, Harada S, Banno S, Wakita A, Kiyoi H, Naoe T, Shimizu S, Sonta SI, Nitta M, Taniwaki M, Ueda R. Hanamura I, et al. Among authors: wakita a. Jpn J Cancer Res. 2001 Jun;92(6):638-44. doi: 10.1111/j.1349-7006.2001.tb01142.x. Jpn J Cancer Res. 2001. PMID: 11429052 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

190 results

Search Page

Filters